XML 69 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Millions
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Additional Paid-in Capital
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Loss
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2021     74,441,312          
Stockholders' equity, beginning of period at Dec. 31, 2021 $ 3,443.8   $ 0.7 $ 3.9 $ 5,182.2   $ (1,770.9) $ 27.9
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) 874.7       889.6     (14.9)
Net income (loss) 889.6              
Payment of dividends to stockholders (404.3)       (404.3)      
Issuance of non-employee director restricted stock (in shares)     10,301          
Issuance of non-employee director restricted stock 1.5     1.5        
Issuance of stock awards (in shares)     250,719          
Issuance of stock awards (19.4)     (6.5) (12.9)      
SSARs exercised (in shares)     12,307          
SSARs exercised (1.2)     (1.2)        
Stock compensation 32.5     32.5        
Distribution to noncontrolling interest (13.8)             (13.8)
Investment by noncontrolling interests 0.1             0.1
Purchases and retirement of common stock (in shares)     (113,824)          
Defined benefit pension and postretirement plans, net of tax (0.8)           (0.8)  
Deferred gains and losses on derivatives, net of tax (0.5)           (0.5)  
Change in cumulative translation adjustment (30.0)           (30.9) 0.9
Ending balance (in shares) at Dec. 31, 2022     74,600,815          
Stockholders' equity, end of period at Dec. 31, 2022 $ 3,882.6 $ (5.5) $ 0.7 30.2 5,654.6 $ (5.5) (1,803.1) 0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2016-13 [Member]              
Redeemable Noncontrolling Interests, Ending balance at Dec. 31, 2023 $ 0.0              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) 1,171.3       1,171.4     (0.1)
Net income (loss) 1,171.4              
Payment of dividends to stockholders (457.4)       (457.4)      
Issuance of non-employee director restricted stock (in shares)     10,524          
Issuance of non-employee director restricted stock 1.5     1.5        
Issuance of stock awards (in shares)     256,709          
Issuance of stock awards (20.5)     (20.5)        
SSARs exercised (in shares)     21,594          
SSARs exercised (2.1)     (2.1)        
Stock compensation 44.9     44.9        
Purchases and retirement of common stock (in shares)     (371,669)          
Purchases and retirement of common stock (53.0)     (49.9) (3.1)      
Defined benefit pension and postretirement plans, net of tax (7.4)           (7.4)  
Deferred gains and losses on derivatives, net of tax 0.1           0.1  
Change in cumulative translation adjustment 102.3           102.3  
Ending balance (in shares) at Dec. 31, 2023     74,517,973          
Stockholders' equity, end of period at Dec. 31, 2023 4,656.8   $ 0.7 4.1 6,360.0   (1,708.1) 0.1
Increase (Decrease) in Temporary Equity [Roll Forward]                
Net income (loss) (60.8)              
Initial fair value of redeemable noncontrolling interests 355.1              
Investment by redeemable noncontrolling interest 8.1              
Change in cumulative translation adjustment (2.3)              
Redeemable Noncontrolling Interests, Ending balance at Dec. 31, 2024 300.1              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) (485.6)              
Net income (loss) (424.8)       (424.8)      
Payment of dividends to stockholders (273.1)       (273.1)      
Issuance of non-employee director restricted stock (in shares)     12,842          
Issuance of non-employee director restricted stock 1.7     1.7        
Issuance of stock awards (in shares)     198,601          
Issuance of stock awards (14.0)     (13.5) (0.5)      
SSARs exercised (in shares)     3,388          
SSARs exercised (0.2)     (0.2)        
Stock compensation 10.2     10.2        
Purchases and retirement of common stock (in shares)     (311,852)          
Purchases and retirement of common stock (22.0)     (5.4) (16.6)      
Sale of minority interest (0.1)             (0.1)
Equity transaction associated with JCA noncontrolling interest 3.1     3.1        
Defined benefit pension and postretirement plans, net of tax 19.8           19.8  
Deferred gains and losses on derivatives, net of tax 9.7           9.7  
Change in cumulative translation adjustment (224.3)           (224.3)  
Ending balance (in shares) at Dec. 31, 2024     74,420,952          
Stockholders' equity, end of period at Dec. 31, 2024 $ 3,742.8   $ 0.7 $ 0.0 $ 5,645.0   $ (1,902.9) $ 0.0